Cover Image

Precision Oncology and Cancer Biomarkers Issues at Stake and Matters of Concern /

Show other versions (2)

This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Bremer, Anne (Editor), Strand, Roger (Editor)
Format: Electronic eBook
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2022.
Edition:1st ed. 2022.
Series:Human Perspectives in Health Sciences and Technology, 5
Subjects:
Medicine > Philosophy.
Bioethics.
Cancer.
Public health.
Medical economics.
Philosophy of Medicine.
Cancer Biology.
Public Health.
Health Economics.
Online Access:Link to Metadata
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Introduction (Anne Bremer and Roger Strand)
  • Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen)
  • Chapter 2. Cancer biomarkers from a patient's perspective (Karen Gissum)
  • Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås)
  • Chapter 4. HER2: an apparently 'simple' biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen)
  • Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti)
  • Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand)
  • Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg)
  • Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand)
  • Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck)
  • Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand)
  • Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns)
  • Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang)
  • Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal)
  • Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer).

Similar Items